No evidence that drinking urine has health benefits, could make health issues worseIN SHORT: A Facebook reel claims that drinking urine helps reabsorb important chemicals that the body lost in the ...

DURHAM, N.C. (WTVD) -- Duke Eye Center has become the first academic medical center in the country to implant a new cell-based gene therapy for a rare eye disease called MacTel. This procedure offers ...

After bursting on the scene with a $70m Series A fundraise, Excellergy is forecasting first-in-human trials for both its lead and next-generation candidates within the next two years, says CEO Todd ...

Eli Lilly has agreed to acquire eye disease specialist Adverum Biotechnologies, bucking a recent trend of big pharma companies deciding to steer clear of the cell and gene therapy sector. Eli Lilly ...

Excellergy plans to initiate Phase I testing of its lead candidate in early 2026 in an ex-US study. Credit: Valeryia Zayats/ShutterStock.com. After bursting on the scene with a $70m Series A fundraise ...

Oct 24 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Friday it would acquire gene therapy developer Adverum Biotechnologies (ADVM.O), opens new tab in a deal valued at up to $261.7 million, ...

Eli Lilly & Co. agreed to buy Adverum Biotechnologies Inc., a company working to treat blindness, in a deal that ultimately could be worth $261.7 million as it continues a push into gene therapies.

Under the merger terms, Eli Lilly will launch a tender offer to acquire all outstanding Adverum shares for up to $12.47 per share, consisting of $3.56 in cash at closing and a non-transferable ...

Just as Adverum Biotechnologies' cash reserves were running dry, Eli Lilly has swooped in to buy the biotech and its phase 3-stage eye disease gene therapy. The prize for Lilly is ixo-vec, an ...